A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT07899632
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-11Est. Completion: 2029-08
Enrollment target: 75 participants Other microbiome trials you might be interested in
Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast CancerHER2-negative Breast CancerInvasive Breast Carcinoma
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitorin…
Indianapolis, United StatesEst. completion Jan 2027
Microbiome
Triple-negative breast cancer (TNBC) is considered a tumor with a high risk of recurrence and metastasis and requires ag…
Essen, GermanyEst. completion Jul 1, 2027